Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review 2024

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review 2024

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) Global Clinical Trials Review 2024

Author: Research and Markets

Published At: 2024-12-26T09:33:00Z

Description:

Company Coverage includes Jazz Pharmaceuticals, UCB, Takeda Pharmaceutical, Biocodex, Longboard Pharmaceuticals, Stoke Therapeutics, Thermo Fisher Scientific, Harmony Biosciences Holdings, Ovid Therapeutics and Sage Therapeutics. Company Coverage includes Jaz…

Full Content:

Dublin, Dec. 26, 2024 (GLOBE NEWSWIRE) -- The "Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy) - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's… [+4657 chars]

Read full article

Related Keywords

news, latest updates, trending topics, global news

Insights

This article highlights recent developments in the world of news. Stay informed with the latest updates on global events, technology, politics, entertainment, and more. Dive into the details to get a comprehensive understanding of this topic.

Comments